Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults ≥ 50 years of age. (Q40275080)

19 September 2017

title

Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults ≥ 50 years of age. (English)

1 reference

19 September 2017

0 references

1

Gustavo H Dayan

1 reference

19 September 2017

2

Joan Bevilacqua

1 reference

19 September 2017

Dorothy Coleman

3

1 reference

19 September 2017

Aileen Buldo

series ordinal

4

1 reference

19 September 2017

George Risi

series ordinal

5

1 reference

19 September 2017

language of work or name

English

0 references

publication date

7 September 2012

1 reference

19 September 2017

1 reference

19 September 2017

volume

30

1 reference

19 September 2017

issue

47

1 reference

19 September 2017

page(s)

6656-6664

1 reference

West Nile virus: epidemiology, clinical presentation, diagnosis, and prevention

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

West Nile encephalitis: an emerging disease in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

Clinical characteristics and functional outcomes of West Nile Fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

The outbreak of West Nile virus infection in the New York City area in 1999

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

7 January 2021

West Nile virus vaccine

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

A live, attenuated recombinant West Nile virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

Development and evaluation of a formalin-inactivated West Nile Virus vaccine (WN-VAX) for a human vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

Vero cell-derived inactivated West Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

An attenuated West Nile prototype virus is highly immunogenic and protects against the deadly NY99 strain: a candidate for live WN vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

Attenuated West Nile viruses bearing 3'SL and envelope gene substitution mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

Preparation and immunogenic properties of a recombinant West Nile subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

Evaluation of the efficacy of a recombinant subunit West Nile vaccine in Syrian golden hamsters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

Protective Antiviral Immunity Conferred by a Nonintegrative Lentiviral Vector-Based Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

Construction of yellow fever/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic tool.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

Evaluation of Chimeric Japanese Encephalitis and Dengue Viruses for Use in Diagnostic Plaque Reduction Neutralization Tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

Development of antigen-specific memory CD8 T cells following live-attenuated chimeric West Nile virus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

Human effector and memory CD8 T cell responses to smallpox and yellow fever vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis anti

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the Philippines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

Priming Effect of Dengue and Yellow Fever Vaccination on the Immunogenicity, Infectivity, and Safety of a Tetravalent Dengue Vaccine in Humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

In vivo synthesis of tumor necrosis factor-alpha in healthy humans after live yellow fever vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

Influence of the IL-1Ra gene polymorphism on in vivo synthesis of IL-1Ra and IL-1beta after live yellow fever vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2012.08.063

10.1016/J.VACCINE.2012.08.063

7 January 2021

Identifiers

DOI

1 reference

19 September 2017

1 reference